A new University College London study featuring 17,604 participants age 45 and up discovered that semaglutide -- a GLP-1 agonist found in weight-loss drugs like Ozempic and Wegovy -- decreases the risk of major adverse cardiovascular events, like a heart attack and stroke, in patients who were of a higher weight or dealing with obesity. These patients also had cardiovascular disease, but didn't have diabetes (the condition semaglutide is primarily used for), and early on in the study, their MACE risk decreased regardless of how much weight they lost or their waist circumference. Their results were compared with those of participants taking a placebo.

After 20 weeks, a reduction in waist size was associated with a greater reduction in MACE compared to weight loss

See Full Page